M
The startup develops inhibitor cells that reprogram regulatory T-cells within the tumor microenvironment to enhance immune responses against solid tumors. Their immunotherapy approach enables cancer patients to achieve a durable immune attack, improving the effectiveness of cancer treatment.
Boston, United States
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops inhibitor cells that reprogram regulatory T-cells within the tumor microenvironment to enhance immune responses against solid tumors. Their immunotherapy approach enables cancer patients to achieve a durable immune attack, improving the effectiveness of cancer treatment.